Trial Updates

The promise of tau aggregation inhibitors in dementia

The Phase III LUCIDITY trial: a tau aggregation inhibitor in patients with Alzheimer’s disease

HERITAGE: the effect of lifestyle interventions in at-risk elderly communities in China

Racial and ethnic minorities more likely to be excluded from trials based on biomarker prescreening

Phase I trial of NK cell therapy in advanced Alzheimer’s disease

How do genetic scores impact the value of lifestyle interventions?

A review of current clinical trials in dementia with Lewy bodies

Ongoing concerns regarding lecanemab: efficacy & adverse events

Phase II study of NE3107 in degenerative dementias

Boosting neurogenesis with NA-831: Phase III trial update

Potential clinical meaningfulness of donanemab data

Topline donanemab results: most positive Phase III data to date

Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials

Use of AD blood-based biomarkers for trial enrolment

Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials

TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab